Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
作者信息
Hogan Marie C, Masyuk Tatyana V
机构信息
Division of Nephrology & Hypertension, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
出版信息
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):154-156. doi: 10.2215/CJN.0000000000000055. Epub 2023 Jan 16.
Abstract
摘要
相似文献
1
Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?常染色体显性多囊肾病中血管加压素2受体和生长抑素受体的联合靶向作用：常染色体显性多囊肾病治疗的一种有前景的方法？
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):154-156. doi: 10.2215/CJN.0000000000000055. Epub 2023 Jan 16.
2
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.即将出现的常染色体显性遗传性多囊肾病治疗方法。
Adv Kidney Dis Health. 2023 May;30(3):245-260. doi: 10.1053/j.akdh.2023.01.003.
3
An update on tolvaptan for autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病的最新进展
Drugs Today (Barc). 2018 Sep;54(9):519-533. doi: 10.1358/dot.2018.54.9.2776624.
4
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.托伐普坦治疗重症新生儿常染色体显性多囊肾病
Pediatr Nephrol. 2017 May;32(5):893-896. doi: 10.1007/s00467-017-3584-9. Epub 2017 Feb 13.
5
Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?反对：托伐普坦治疗常染色体显性遗传多囊肾病——我们是否已了解所有答案？
Nephrol Dial Transplant. 2019 Jan 1;34(1):35-37. doi: 10.1093/ndt/gfy298.
6
[ADPKD treatment: Tolvaptan and Octreotide].[常染色体显性多囊肾病的治疗：托伐普坦和奥曲肽]
G Ital Nefrol. 2019 Dec 9;36(6):2019-vol6.
7
Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.血浆生长抑素与常染色体显性遗传多囊肾病患者疾病严重程度和进展的关系。
BMC Nephrol. 2018 Dec 19;19(1):368. doi: 10.1186/s12882-018-1176-y.
8
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.TEMPO（托伐普坦治疗常染色体显性遗传多囊肾病及其结局的疗效和安全性）3-4 研究的原理和设计。
Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
9
Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.血管加压素 2 型受体信号转导与常染色体显性遗传多囊肾病：从基础到临床再到基础。
J Am Soc Nephrol. 2014 Jun;25(6):1140-7. doi: 10.1681/ASN.2013101037. Epub 2014 Feb 20.
10
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?探讨血管加压素拮抗剂在多囊肾病中的作用：从成人到儿童？
Pediatr Nephrol. 2018 Mar;33(3):395-408. doi: 10.1007/s00467-017-3672-x. Epub 2017 Apr 28.
引用本文的文献
1
Transforming advancing autosomal dominant polycystic kidney disease care: investigating new horizons in treatment and research.转变进行性常染色体显性多囊肾病的治疗：探索治疗与研究的新领域
Inflammopharmacology. 2025 Aug 14. doi: 10.1007/s10787-025-01894-9.
本文引用的文献
1
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.奥曲肽长效释放制剂联合托伐普坦治疗常染色体显性遗传多囊肾病的效果：一项先导、随机、安慰剂对照、交叉试验。
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223-233. doi: 10.2215/CJN.0000000000000049.
2
Drug management of autosomal dominant polycystic kidney disease.常染色体显性多囊肾病的药物治疗
Aust Prescr. 2022 Oct;45(5):167-170. doi: 10.18773/austprescr.2022.052. Epub 2022 Oct 4.
3
Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis.托伐普坦治疗常染色体显性多囊肾病的疗效和安全性：一项荟萃分析。
Int Urol Nephrol. 2023 Mar;55(3):631-640. doi: 10.1007/s11255-022-03353-8. Epub 2022 Sep 7.
4
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.生长抑素在肾脏生理学和常染色体显性遗传性多囊肾病中的作用。
Nephrol Dial Transplant. 2020 Aug 1;35(8):1306-1316. doi: 10.1093/ndt/gfz054.
5
The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease.在多囊肾病小鼠的囊肿生长过程中，生长抑素受体 2 的表达减少。
Exp Biol Med (Maywood). 2018 Sep;243(13):1092-1098. doi: 10.1177/1535370218803893. Epub 2018 Sep 27.
6
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗常染色体显性遗传多囊肾病的长期疗效观察。
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.
7
Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.长效奥曲肽治疗4年对重症多囊肝病患者的疗效
Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.
8
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.托伐普坦联合帕瑞肽在 PKD1 模型中显示出增强的疗效。
J Am Soc Nephrol. 2015 Jan;26(1):39-47. doi: 10.1681/ASN.2013121312. Epub 2014 Jul 3.
9
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.靶向 cAMP 信号通路治疗多囊肾病的策略。
J Am Soc Nephrol. 2014 Jan;25(1):18-32. doi: 10.1681/ASN.2013040398. Epub 2013 Dec 12.
Zotero 插件